<DOC>
	<DOCNO>NCT00004925</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I/II trial study effectiveness liposomal doxorubicin trastuzumab treat woman locally advance , inflammatory , metastatic breast cancer .</brief_summary>
	<brief_title>Liposomal Doxorubicin Trastuzumab Treating Women With Locally Advanced , Inflammatory , Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety , especially cardiac safety , doxorubicin HCl liposome trastuzumab ( Herceptin ) first- second-line therapy woman metastatic , inflammatory , locally advanced breast cancer . OUTLINE : Patients stratify accord prior anthracycline therapy ( yes v ) . Patients receive doxorubicin HCl liposome IV 1 hour follow 30 minute later trastuzumab ( Herceptin ) IV 30-90 minute day 1 , 8 , 15 . Treatment continue every 21 day absence unacceptable toxicity disease progression . Patients follow least 3 month . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally advance , inflammatory , metastatic adenocarcinoma breast treat 1 prior systemic cytotoxic regimen Overexpression HER2 protein ( 2+ 3+ ) Evaluable disease History brain metastasis allow steroid asymptomatic , 3 month great interval since last dose brain irradiation , evidence progression Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) Renal : AST ALT great 4 time ULN Cardiovascular : Adequate cardiac function LVEF least 50 % predict low limit normal Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent medical psychological condition would preclude study compliance No history hypersensitivity anthracyclines , egg , egg product PRIOR CONCURRENT THERAPY : Biologic therapy : Prior trastuzumab ( Herceptin ) allow Chemotherapy : See Disease Characteristics At least 3 week since prior antineoplastic therapy No 1 prior systemic cytotoxic regimen locally advance , metastatic , inflammatory breast cancer No prior anthracyclines great 240 mg/m2 No concurrent antineoplastic agent No concurrent treatment liposomal product doxorubicin HCl liposome Endocrine therapy : See Disease Characteristics At least 3 week since prior hormonal agent No concurrent hormonal therapy Radiotherapy : See Disease Characteristics Surgery : Not specify Other : At least 3 week since prior investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
</DOC>